5CAPRIE Steering Committee. A randomised, blinded,trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)[J]. Lancet, 1996, 348(9038):1329-1339.
6Love BB, Biller J, Gent M. Adverse haematological effect of ticlopidine. Prevention, recognition and management[J]. Drug Saf, 1998, 19(2): 89-98.
7Bennett CL, Connors JM, Carwile JM, etal. Thrombotic thrombocytopenic purpura associated with clopidogrel[J]. N Engl J Med, 2000, 342(24): 1773-1778.
8Steinhubl SR, Tan WA, Foody JM, et al. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting EPISTE-NT investigators. Evaluation of platelet Ⅱb/Ⅲa inhibitor for stenting[J]. JAMA, 1999, 281(9): 806-810.
9Bennett CL, Davidson C J, Raisch DW, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention[J]. Arch Intern Med, 1999, 159(21): 2524-2528.
10Zusman RM, Chesebro JH, Comerota A, et al. Antiplatelet therapy in the prevention of ischemic vascular events: Literature review and evidence-based guidelines for drug selection[J]. Clin Cardiol, 1999, 22(9): 559-573.
